

PRECEPTORSHIP PROGRAMME

Lung Cancer

Multidisciplinary management,
standards of care and future
perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

19-21 OCTOBER 2020

Co-Chairs

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

[esmo.org](https://www.esmo.org)

ESMO-THE CHRISTIE VIRTUAL PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

19-21 October 2020

CO-CHAIRS:

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

SPEAKERS:

Mo Al Aloul, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Anne-Marie C. Dingemans, Netherlands
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Martin Früh, Switzerland
Pilar Garrido López, Spain
Keith M. Kerr, United Kingdom
Rohit Kochhar, United Kingdom
Cécile Le Péchoux, France
Catherine McBain, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Suresh Senan, Netherlands
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Paul E. Van Schil, Belgium
Giulia Veronesi, Italy
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



All timings are to be considered CEST (Central European Summer Time)

Monday, 19 October 2020

14:00-14:10 10'	Welcome and Introduction	Fiona Blackhall, UK Raffaele Califano, UK Enriqueta Felip, ES
14:10-15:20 70'	SESSION 1 Screening and diagnostics for lung cancer	Chair/Moderator: Raffaele Califano, UK
20'	Lung cancer screening	Haval Balata, UK
20'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
20'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
10'	Discussion	Faculty
15:20-15:30	Break	
15:30-16:20 50'	SESSION 1 - cont. Screening and diagnostics for lung cancer	Chairs/Moderators: Fiona Blackhall, UK Raffaele Califano, UK
20'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
20'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
10'	Discussion	Faculty
16:20-17:50 90'	SESSION 2 Radical treatment of early stage NSCLC	Chair/Moderator: Raffaele Califano, UK
20'	Surgery for early stage NSCLC	Giulia Veronesi, IT
20'	Stereotactic ablative RT for early stage NSCLC	Suresh Senan, NL
20'	Adjuvant RT for completely resected early stage NSCLC	Cécile Le Péchoux, FR
20'	Adjuvant chemotherapy for resected early stage NSCLC	Paul Taylor, UK
10'	Discussion	Faculty
17:50-18:00 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK

Tuesday, 20 October 2020

14:00-16:30 140'	SESSION 3 Advanced NSCLC	Chair/Moderator: Fiona Blackhall, UK
20'	First-line chemotherapy for advanced NSCLC	David Planchard, FR
20'	First-line immune checkpoint blockade for NSCLC	Luis Paz-Ares, ES
20'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
10'	Discussion	Faculty
15:10-15:20	Break	
20'	Treatment of ALK/ROS1 positive advanced NSCLC	Fiona Blackhall, UK
20'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK

20'	Beyond ALK /ROS1 and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
10'	Discussion	Faculty
16:30-17:40 70'	SESSION 4 Management of mesothelioma, oligometastatic NSCLC and brain metastases	Chair/Moderator: Raffaele Califano, UK
20'	Systemic treatment of mesothelioma	Paul Baas, NL
20'	Treatment of oligometastatic NSCLC	Anne-Marie C. Dingemans, NL
20'	Radical treatment of brain metastases: The importance of a neuro-oncology multidisciplinary approach	Catherine McBain, UK
10'	Discussion	Faculty
17:40-17:45 5'	Close of day 2	Fiona Blackhall, UK Raffaele Califano, UK

Wednesday, 21 October 2020

14:00-16:05 115'	SESSION 5 Locally advanced NSCLC	Chairs/Moderators: Fiona Blackhall, UK Enriqueta Felip, UK
20'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
20'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
20'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10'	Discussion	Faculty
15:10-15:20	Coffee break	
45'	Participants clinical case discussion (3x15')	Faculty

Each 15 min slot for clinical case discussion includes 10' case presentation and 5' Q&A / interactive panel discussion

16:05-17:55 110'	SESSION 6 SCLC	Chairs/Moderators: Raffaele Califano, UK Enriqueta Felip, ES
20'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
20'	Chemotherapy for extensive stage SCLC	Martin Früh, CH
20'	Immune Checkpoint blockade for SCLC	Pilar Garrido López, ES
20'	Targeted agents in SCLC	Enriqueta Felip, ES
20'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
10'	Discussion	Faculty
17:55-18:00 5'	Conclusion and farewell	Fiona Blackhall, UK Raffaele Califano, UK Enriqueta Felip, ES